ADCT

ADC Therapeutics SA is a commercial-stage biotechnology company focused on developing and commercializing proprietary antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's lead product, ZYLO (loncastuximab tesirine-lpyl), is approved for treating relapsed or refractory diffuse large B-cell lymphoma. ADC Therapeutics' pipeline includes additional oncology programs targeting various cancers using its proprietary pyrrolobenzodiazepine (PBD) warhead technology, which delivers highly potent cell-killing agents directly to cancer cells via targeted antibodies. This approach aims to maximize anti-tumor efficacy while minimizing systemic toxicity. The company is conducting clinical trials to expand ZYLO's indications and develop next-generation ADC candidates. Headquartered in Lausanne, Switzerland, with U.S. operations in New Jersey, ADC Therapeutics was founded in 2011. The company operates in the rapidly evolving ADC sector, competing with established pharmaceutical companies and emerging biotechs. Success depends on clinical trial outcomes, regulatory approvals, commercialization execution, and reimbursement access in the competitive oncology therapeutics market.